Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
U.S. ZEVTERA IV prodrug doses: 667 mg ceftobiprole medocaril sodium is equivalent to 500 mg ceftobiprole; 333 mg is equivalent to 250 mg. Not an international 500 mg vial instruction.
Renal method
Creatinine clearance in mL/min; adult U.S. product table
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
U.S. product labeling / DailyMed · U.S. ZEVTERA IV prodrug doses: 667 mg ceftobiprole medocaril sodium is equivalent to 500 mg ceftobiprole; 333 mg is equivalent to 250 mg. Not an international 500 mg vial instruction.
Renal method: Creatinine clearance in mL/min; adult U.S. product table Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Adult renal table - U.S. prodrug dose units
CrCl
S. aureus bacteremia
ABSSSI or community-acquired bacterial pneumonia
30 to below 50
667 mg every 8 hours on days 1-8, then every 12 hours
667 mg every 12 hours
15 to below 30
333 mg every 8 hours on days 1-8, then every 12 hours
333 mg every 12 hours
Below 15, including hemodialysis
333 mg every 24 hours
333 mg every 24 hours
Administer each dose by a 2-hour IV infusion. On hemodialysis days, administer after dialysis.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.